Showing 1371-1380 of 1581 results for "".
- The Skinny on TikTok Face and Other Social Media Beauty Hackshttps://modernaesthetics.com/news/tiktok-face-and-other-social-media-beauty-hacks/2473267/“TikTok Face” is the media-given name for all sorts of poses (think shielding your face like you're evading the paparazzi) and hacks such as taping to reduce wrinkles or contouring with sunscreen so you look better in your photos and in person. And it’s c
- Coming Soon: An Increased Demand for Plus-Sized Body Contouring Procedureshttps://modernaesthetics.com/news/coming-soon-an-increased-demand-for-plus-sized-body-contouring-procedures/2473266/Plus size models have gained in popularity in the fashion business and on social media, and plastic surgeons will likely see an increased demand for procedures that enhance the plus size body type, according to researchers from Boston University School of Medicine (BUSM).
- New from TruSkin: TruSkin SPF 30 Mineral Sunscreen with Vitamin Chttps://modernaesthetics.com/news/new-from-truskin-truskin-spf-30-mineral-sunscreen-with-vitamin-c/2473257/New from TruSkin, TruSkin SPF 30 Mineral Sunscreen with Vitamin C features non-nano zinc oxide in a lightweight, non-greasy formula with asheer finish intended to blend into all 
- Trend Alert: New Allergan Aesthetics Report Highlights What’s to Comehttps://modernaesthetics.com/news/trend-alert-new-allergan-aesthetics-report-highlights-whats-to-come/2473254/Consumer interest in medical aesthetics continues to rise, with the number of dermal filler treatments worldwide growing by almost two million between 2017 and 2020, according to Allergan Aesthetics’ 'The Future of Aesthetics' global trends report. In addition, the r
- Apyx Medical Corporation Scores FDA 510(k) Clearance for Renuvion Handpiecehttps://modernaesthetics.com/news/apyx-medical-corporation-scores-fda-510k-clearance-for-renuvion-handpiece/2473245/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to
- Crown Laboratories to Acquire Eclipse Aesthetics Assetshttps://modernaesthetics.com/news/crown-laboratories-to-acquire-eclipse-aesthetics-assets/2473242/Crown Laboratories will acquire the global aesthetics-focused assets of Eclipse. The acquisition expands Crown's aesthetics' product portfolio and enhances Crown's overall value proposition as a global leader in science-based aesthetic skincare solutions.
- Cynosure Receives $60 Million Follow-on Investment from Clayton, Dubilier & Ricehttps://modernaesthetics.com/news/cynosure-recieves-60-million-follow-on-investment-from-clayton-dubilier-rice/2473237/Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its cust
- New Ophthalmologist-Created Eye Skincare Line Launcheshttps://modernaesthetics.com/news/new-ophthalmologist-created-eye-skincare-line-launches/2473236/Now available for pre-order, Daily Practice, the new eye care line by Ashley Brissette, MD, has launched with a hero product—Eye Revive. Having worked as an ophthalmologist for six years, New York City-based Dr. Brissette says she recognized a grow
- Dr. Jennifer Walden Named President of the Aesthetic Societyhttps://modernaesthetics.com/news/dr-jennifer-walden-named-president-of-the-aesthetic-society/2473231/Austin, TX-based Jennifer Walden, MD is the first female Aesthetic Society President. "I am looking forward to serving The Aesthetic Society as its first female president. Born in 1971, I believe it was Title IX1 that set the stage for me as a young girl. I was
- Revance News: FDA Accepts BLA Resubmission for DaxibotulinumtoxinAhttps://modernaesthetics.com/news/revance-news-fda-accepts-bla-resubmission-for-daxibotulinumtoxina/2473223/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont